EMEA-002642-PIP01-19-M03

Key facts

Active substance
Ladarixin
Therapeutic area
Endocrinology, -gynacology-fertility-metabolism
Decision number
P/0144/2021
PIP number
EMEA-002642-PIP01-19-M03
Pharmaceutical form(s)
  • Age-appropriate oral liquid dosage form
  • Capsule, hard
Condition(s) / indication(s)
Treatment of type I diabetes mellitus
Route(s) of administration
Oral use
Contact for public enquiries
Dompé farmaceutici S.p.A

E-mail: dar@dompe.com
Tel.: +39 02583831

Decision type
PM: decision on the application for modification of an agreed PIP

Decision

How useful was this page?

Add your rating